eMedicine Specialties > Dermatology > Diseases of the Subcutaneous Tissue

Erythema Nodosum

Author: Jeanette L Hebel, MD, Department of Dermatology, Lancaster General Hospital
Coauthor(s): Thomas Habif, MD, Adjunct Professor, Department of Internal Medicine, Section of Dermatology, Dartmouth Medical School
Contributor Information and Disclosures

Updated: Jan 22, 2009

Introduction

Background

Erythema nodosum (EN) is an acute, nodular, erythematous eruption that usually is limited to the extensor aspects of the lower legs. Chronic or recurrent erythema nodosum is rare but may occur. Erythema nodosum is presumed to be a hypersensitivity reaction and may occur in association with several systemic diseases or drug therapies, or it may be idiopathic. The inflammatory reaction occurs in the panniculus.

Pathophysiology

Erythema nodosum probably is a delayed hypersensitivity reaction to a variety of antigens; circulating immune complexes have not been found in idiopathic or uncomplicated cases but may be demonstrated in patients with inflammatory bowel disease.1

Frequency

United States

Peak incidence occurs at age 18-34 years. Age and sex distributions vary according to etiology and geographic location.2

International

Rates of erythema nodosum vary according to country. In England, the rate is 2.4 cases per 10,000 per year.

Mortality/Morbidity

In most patients, erythema nodosum resolves without any adverse reactions.

Sex

Women are affected more often than men, with a male-to-female ratio of 1:4.

Age

Erythema nodosum may occur in children and in patients older than 70 years, but it is more common in young adults aged 18-34 years. Age distribution varies with geographic location and etiology.

Clinical

History

The eruptive phase of erythema nodosum begins with flulike symptoms of fever and generalized aching. Arthralgia may occur and precedes the eruption or appears during the eruptive phase. Most lesions in infection-induced erythema nodosum heal within 7 weeks, but active disease may last up to 18 weeks. In contrast, 30% of idiopathic erythema nodosum cases may last more than 6 months. Febrile illness with dermatologic findings includes abrupt onset of illness with initial fever, followed by a painful rash within 1-2 days.

Physical

Pertinent physical findings are limited to the skin and joints.

Primary skin lesions

Lesions begin as red tender nodules (see the image below). Lesion borders are poorly defined, and lesions vary from 2-6 cm. During the first week, lesions become tense, hard, and painful; during the second week, they may become fluctuant, as in an abscess, but do not suppurate or ulcerate. Individual lesions last approximately 2 weeks, but occasionally, new lesions continue to appear for 3-6 weeks. Aching legs and swelling ankles may persist for weeks.

Classic presentation of erythema nodosum with nod...

Classic presentation of erythema nodosum with nodular red swellings over the shins.

Classic presentation of erythema nodosum with nod...

Classic presentation of erythema nodosum with nodular red swellings over the shins.



Distribution of skin lesions

Characteristically, lesions appear on the anterior leg; however, they may appear on any surface.

Color of skin lesions

Lesions change color in the second week from bright red to bluish or livid. As absorption progresses, the color gradually fades to a yellowish hue, resembling a bruise. This disappears in 1 or 2 weeks as the overlying skin desquamates.

Hilar lymph nodes

Hilar adenopathy may develop as part of the hypersensitivity reaction of erythema nodosum. Bilateral hilar lymphadenopathy is associated with sarcoidosis, while unilateral changes may occur with infections and malignancy.

Joints

Arthralgia occurs in more than 50% of patients and begins during the eruptive phase or precedes the eruption by 2-4 weeks. Erythema, swelling, and tenderness occur over the joint, sometimes with effusions. Joint tenderness and morning stiffness may occur. Any joint may be involved, but the ankles, knees, and wrist are affected most commonly. Synovitis resolves within a few weeks, but joint pain and stiffness may last up to 6 months. No destructive joint changes occur. Synovial fluid is acellular, and the rheumatoid factor is negative.

Causes

Currently, the most common cause of erythema nodosum is streptococcal infection in children and streptococcal infection and sarcoidosis in adults.3 Numerous other causes have been reported.4 The causes reported most often in the literature are as follows:

  • Bacterial infections
    • Streptococcal infections are one of the most common causes of erythema nodosum.
    • Tuberculosis was an important cause in the past, but it has decreased dramatically as a cause for erythema nodosum; however, it still must be excluded, especially in developing countries.5,6
    • Yersinia enterocolitica is a gram-negative bacillus that causes acute diarrhea and abdominal pain; it is a common cause of erythema nodosum in France and Finland.7,8,9
    • Mycoplasma pneumoniae infection may cause erythema nodosum.
    • Erythema nodosum leprosum clinically resembles erythema nodosum, but the histologic picture is that of leukocytoclastic vasculitis.
    • Lymphogranuloma venereum may cause erythema nodosum.
    • Salmonella infection may cause erythema nodosum.
    • Campylobacter infection may cause erythema nodosum.
  • Fungal infections
    • Coccidioidomycosis (San Joaquin Valley fever) is the most common cause of erythema nodosum in the American Southwest. In approximately 4% of males and 10% of females, the primary fungal infection (which may be asymptomatic or involve symptoms of upper respiratory infection) is followed by the development of erythema nodosum. Lesions appear 3 days to 3 weeks after the end of the fever caused by the fungal infection.
    • Histoplasmosis may cause erythema nodosum.
    • Blastomycosis may cause erythema nodosum.
  • Drugs: Sulfonamides and halide agents are an important cause of erythema nodosum. Drugs more recently described to cause erythema nodosum include gold and sulfonylureas. Oral contraceptive pills are implicated in an increasing number of reports.
  • Enteropathies: Ulcerative colitis and Crohn disease may trigger erythema nodosum. Erythema nodosum associated with enteropathies correlates with flares of the disease. The mean duration of chronic ulcerative colitis before the onset of erythema nodosum is 5 years, and erythema nodosum is controlled with adequate therapy of the colitis.  Erythema nodosum is the most frequent dermatologic symptom in inflammatory bowel diseases, and it is strongly associated with Crohn disease.10
  • Hodgkin disease and lymphoma: Erythema nodosum associated with non-Hodgkin lymphoma may precede the diagnosis of lymphoma by months. Reports of erythema nodosum preceding the onset of acute myelogenous leukemia have been published.11
  • Sarcoidosis: The most common cutaneous manifestation of sarcoidosis is erythema nodosum. A characteristic form of acute sarcoidosis involves the association of erythema nodosum, hilar lymphadenopathy, fever, arthritis, and uveitis, which has been termed Lofgren syndrome. This presentation has a good prognosis with complete resolution within several months in most patients.
  • Behçet disease (associated with erythema nodosum)
  • Pregnancy: Some patients develop erythema nodosum during pregnancy, most frequently during the second trimester. Repeated episodes occur with subsequent pregnancies or with the use of oral contraceptives.

More on Erythema Nodosum

Overview: Erythema Nodosum
Differential Diagnoses & Workup: Erythema Nodosum
Treatment & Medication: Erythema Nodosum
Follow-up: Erythema Nodosum
Multimedia: Erythema Nodosum
References

References

  1. Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. May 2006;101(5):1012-23. [Medline].

  2. Mert A, Ozaras R, Tabak F, Pekmezci S, Demirkesen C, Ozturk R. Erythema nodosum: an experience of 10 years. Scand J Infect Dis. 2004;36(6-7):424-7. [Medline].

  3. Hassink RI, Pasquinelli-Egli CE, Jacomella V, Laux-End R, Bianchetti MG. Conditions currently associated with erythema nodosum in Swiss children. Eur J Pediatr. Nov 1997;156(11):851-3. [Medline].

  4. Mert A, Ozaras R, Tabak F, Ozturk R. Primary tuberculosis cases presenting with erythema nodosum. J Dermatol. Jan 2004;31(1):66-8. [Medline].

  5. Kakourou T, Drosatou P, Psychou F, Aroni K, Nicolaidou P. Erythema nodosum in children: a prospective study. J Am Acad Dermatol. Jan 2001;44(1):17-21. [Medline].

  6. Puavilai S, Sakuntabhai A, Sriprachaya-Anunt S, Rajatanavin N, Charuwichitratana S. Etiology of erythema nodosum. J Med Assoc Thai. Feb 1995;78(2):72-5. [Medline].

  7. Bottone EJ. Yersinia enterocolitica: the charisma continues. Clin Microbiol Rev. Apr 1997;10(2):257-76. [Medline].

  8. Labbe L, Perel Y, Maleville J, Taieb A. Erythema nodosum in children: a study of 27 patients. Pediatr Dermatol. Nov-Dec 1996;13(6):447-50. [Medline].

  9. Stolk-Engelaar VM, Hoogkamp-Korstanje JA. Clinical presentation and diagnosis of gastrointestinal infections by Yersinia enterocolitica in 261 Dutch patients. Scand J Infect Dis. 1996;28(6):571-5. [Medline].

  10. Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore). Sep 2008;87(5):281-93. [Medline].

  11. Sullivan R, Clowers-Webb H, Davis MD. Erythema nodosum: a presenting sign of acute myelogenous leukemia. Cutis. Aug 2005;76(2):114-6. [Medline].

  12. Moraes AJ, Soares PM, Zapata AL, Lotito AP, Sallum AM, Silva CA. Panniculitis in childhood and adolescence. Pediatr Int. Feb 2006;48(1):48-53. [Medline].

  13. Requena L, Yus ES. Panniculitis. Part I. Mostly septal panniculitis. J Am Acad Dermatol. Aug 2001;45(2):163-83; quiz 184-6. [Medline].

  14. Marshall JK, Irvine EJ. Successful therapy of refractory erythema nodosum associated with Crohn's disease using potassium iodide. Can J Gastroenterol. Sep 1997;11(6):501-2. [Medline].

  15. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol. Dec 1996;35(6):969-79. [Medline].

Further Reading

Keywords

erythema nodosum, EN, delayed hypersensitivity reaction, erythematous eruption, nodular eruption, panniculus, arthralgia, infection-induced EN, idiopathic EN, red tender nodules, aching legs, swollen ankles, hilar adenopathy, morning stiffness, joint tenderness, synovitis, streptococcal infection, sarcoidosis, tuberculosis

Yersinia enterocolitica, Mycoplasma pneumoniae, leprosy, lymphogranuloma venereum, Salmonella infection, Campylobacter infection, coccidioidomycosis, San Joaquin Valley fever, histoplasmosis, blastomycosis, ulcerative colitis, Crohn disease, enteropathies, chronic ulcerative colitis, lymphoma EN, uveitis, Lofgren syndrome, Behçet disease

Contributor Information and Disclosures

Author

Jeanette L Hebel, MD, Department of Dermatology, Lancaster General Hospital
Jeanette L Hebel, MD is a member of the following medical societies: American Academy of Dermatology and American College of Mohs Surgery
Disclosure: Nothing to disclose.

Coauthor(s)

Thomas Habif, MD, Adjunct Professor, Department of Internal Medicine, Section of Dermatology, Dartmouth Medical School
Thomas Habif, MD is a member of the following medical societies: American Academy of Dermatology and New Hampshire Medical Society
Disclosure: Nothing to disclose.

Medical Editor

Timothy McCalmont, MD, Director, UCSF Dermatopathology Service, Professor of Clinical Pathology and Dermatology, Departments of Pathology and Dermatology, University of California at San Francisco; Editor-in-Chief, Journal of Cutaneous Pathology
Timothy McCalmont, MD is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, American Society of Dermatopathology, California Medical Association, College of American Pathologists, and United States and Canadian Academy of Pathology
Disclosure: Apsara Consulting fee Independent contractor

Pharmacy Editor

David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic
David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Managing Editor

Edward F Chan, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine
Edward F Chan, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds Investigator; Genentech Grant/research funds investigator; Centocor Consulting fee Consulting; Abbott Grant/research funds investigator; Abbott Consulting fee Consulting; Novartis  investigator; Pfizer Grant/research funds investigator; Celgene Consulting fee DMC Chair; NIAMS and NHLBI Grant/research funds investigator

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.